SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to review new and updated clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader progr ...

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3] - The CEO, Michael A. Metzger, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025 [1] - A live webcast of the event will be available on the company's website, along with a replay for a limited time [2] Company Overview - Syndax's pipeline includes FDA-approved therapies such as Revuforj (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor [3] - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3]

Core Viewpoint - NioBay Metals Inc. has announced a private placement agreement with Red Cloud Securities Inc. to raise up to C$5,000,000 for its James Bay Niobium Project and general corporate purposes [1][4]. Group 1: Offering Details - The private placement will consist of Units, FT Units, and Charity FT Units, with each Unit comprising one common share and one warrant [2][3]. - The pricing for the Units is set at C$0.14, FT Units at C$0.16, and Charity FT Units at C$0.21 [8]. - An additional option allows Red Cloud to sell up to C$1,000,000 in any combination of Units, FT Units, and Charity FT Units prior to the closing [3]. Group 2: Use of Proceeds - The net proceeds from the Offering will be allocated to the exploration and advancement of the James Bay Niobium Project, as well as for working capital and general corporate purposes [4]. - Proceeds from the sale of FT Shares will specifically be used for eligible Canadian exploration expenses related to the James Bay Niobium Project [5]. Group 3: Regulatory and Compliance - The Offering will comply with applicable regulatory requirements and will be offered in several Canadian provinces under the Listed Issuer Financing Exemption [6][7]. - The Offering is scheduled to close on December 18, 2025, subject to necessary regulatory approvals [10]. Group 4: Company Overview - NioBay aims to lead in low carbon consumption mining practices while ensuring the participation of Indigenous communities in its operations [12]. - The company holds a 100% interest in the James Bay Niobium Project and a 72.5% interest in the Crevier Niobium and Tantalum project [12]. Group 5: Industry Context - Niobium is a highly valuable metal used in various sectors, enhancing material properties and reducing environmental impacts [13].

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, M ...

New analysis highlights how congestion around major U.S. airports changed during the federal shutdown and key holiday travel periodsAMSTERDAM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- TomTom (TOM2), the location technology specialist, today released a new report examining how road congestion around major U.S. airports shifts during the country’s busiest travel periods, including the recent federal shutdown that stretched across November and contributed to widespread flight cancellations. Drawing on multi-year data ...

TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Highlander Silver Corp. (TSX: HSLV; “Highlander Silver” or the “Company”) is pleased to report exceptional assay results from shallow drilling at its expanding Bonita vein system. These results include the highest grades reported to date and the discovery of a new zone in step-out drilling over 200m northwest of prior holes along trend. The Bonita vein system is exposed along a ridgeline approximately 10km to the south of the bonanza grade Ayelen deposit at the San ...

TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) (“Carlton” or the “Company”) is pleased to provide an update to investors on its Esquilache Silver project (“Esquilache” or the “Project”) located in the Puno region of Southern Peru. Esquilache covers 1,600 hectares that include historical mine workings formally developed by Hochschild Mining PLC (“Hochschild”). Carlton owns the project 100% and royalty free after buying back the Project's royalties in 2022. Althou ...

~ Gross margin expected to increase from 39.6% to 50.5% ~ ~ Loss from operations expected to be cut nearly in half ~ IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (“Mobix” or the “Company”) today announced selected preliminary, unaudited financial results for its fourth quarter and fiscal year ended September 30, 2025. The preliminary financial information presented in this release is based on information available to the Company as of the date of this release and remains subject to com ...

Core Points - Patrick D. Walsh will retire as Chairman of ANI Pharmaceuticals, effective after the 2026 Annual Meeting of Stockholders, having served the company with distinction [1][2] - Thomas J. Haughey has been unanimously elected as the new Chairman of the Board, having been a member since May 2018 [1][2] - Haughey will step down from his role as Chair of the Audit and Finance Committee, with Jeanne Thoma taking over that position [2] Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [3] - The company aims to deliver sustainable growth through its Rare Disease business, Generics business, and Brands business, targeting areas such as ophthalmology, rheumatology, nephrology, neurology, and pulmonology [3]

Core Viewpoint - Signing Day Sports, Inc. is progressing towards a business combination with BlockchAIn Digital Infrastructure, Inc. and One Blockchain LLC, aiming to enhance its recruitment platform for high school athletes and college coaches through this strategic alignment [1][2]. Company Overview - Signing Day Sports is focused on improving the recruiting process for student-athletes, providing a platform that allows them to create recruitment profiles with necessary information for college coaches [3]. - One Blockchain LLC specializes in digital infrastructure, particularly in Bitcoin mining and high-performance computing, operating a significant data center in South Carolina that generated approximately $22.9 million in revenue and $5.7 million in net income in 2024 [4]. Business Combination Details - The Registration Statement on Form S-4 has been filed with the SEC, detailing the proposed business combination and the listing of BlockchAIn common shares on NYSE American under the ticker symbol "AIB" [1][2]. - The business combination agreement was initially entered into on May 27, 2025, and amended on November 10, 2025, marking a significant milestone for both companies [2]. Strategic Benefits - The combined entity is expected to leverage Signing Day Sports' technology-driven recruitment platform alongside One Blockchain's digital infrastructure, enhancing financial flexibility and technical capabilities [2]. - This merger is anticipated to accelerate innovation, expand market opportunities, and strengthen the competitive position of the combined company, ultimately creating long-term value for shareholders [2].